A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).

Trial Details

NCT ID
NCT07111832
Phase
PHASE3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • SHR-A1811 for Injection
  • SHR-1316 Injection
  • Toripalimab Injection
  • Paclitaxel for Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18-75 years old (including both ends), female.
  • Pathologically confirmed locally recurrent unresectable or metastatic triple-negative breast cancer.
  • Expected survival ≥ 12 weeks.
  • Have adequate renal and hepatic function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →